Results 11 to 20 of about 192,839 (256)

Faricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice [PDF]

International Journal of Retina and Vitreous
Purpose To evaluate the clinical outcomes of the switch to faricimab in a treat-and-extend (T&E) regimen patients with neovascular age-related macular degeneration (nAMD).
Jorge Ruiz-Medrano, Iulia Pana, María García-Zamora, Ignacio Flores-Moreno, Mariluz Puertas, José Mª Ruiz-Moreno   +5 more
doaj   +2 more sources

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result [PDF]

Pharmaceuticals, 2023
We aimed to investigate whether a treat-and-extend regimen of intravitreal brolucizumab (6.0 mg/0.05 mL) is effective for eyes with exudative age-related macular degeneration (AMD) refractory to aflibercept for 12 months.
Wataru Kikushima, Yoichi Sakurada, Yoshiko Fukuda, Mio Matsubara, Yumi Kotoda, Atsushi Sugiyama, Kenji Kashiwagi   +6 more
doaj   +2 more sources

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice [PDF]

Ophthalmology and Therapy
Introduction Anti-vascular endothelial growth factor (VEGF) is generally given using pro re nata or “treat-and-extend” (T&E) regimens for neovascular age-related macular degeneration (nAMD).
Eloi Debourdeau, Helene Beylerian, Vuong Nguyen, Daniel Barthelmes, Mark Gillies, Pierre Henry Gabrielle, Stela Vujosevic, Louise Otoole, Martin Puzo, Catherine Creuzot-Garcher, Benjamin Wolff, Vincent Daien, The Fight Retinal Blindness! Study Group   +12 more
doaj   +2 more sources

OCT biomarkers as predictors of treatment interval in neovascular age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen [PDF]

Scientific Reports
Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss in older adults. Treat-and-extend (T&E) regimen for anti-vascular endothelial growth factor therapy are widely used to individualize treatment, yet substantial ...
Jae Hyup Lee, Sang-Yoon Lee, Boa Jang, Young-Gon Kim, Chang Ki Yoon, Un Chul Park, Kyu Hyung Park, Eun Kyoung Lee   +7 more
doaj   +2 more sources

Real-World Outcomes of Aflibercept 2 mg Using a Treat-and-Extend Protocol for Neovascular Age-Related Macular Degeneration: A 24-Month Retrospective Study in a Chinese Population [PDF]

Drug Design, Development and Therapy
Yuanyuan Qi,* Aixuan Cheng,* Jiayang Xu, Chao Zhang, Sheng Li Department of Ophthalmology, Dalian Third People’s Hospital Affiliated to Dalian University of Technology, Dalian, People’s Republic of China*These authors contributed ...
Qi Y, Cheng A, Xu J, Zhang C, Li S
doaj   +2 more sources

Efficacy and safety of treat-and-extend intravitreal brolucizumab in naive and switched patients with macular neovascularization: one-year follow-up study [PDF]

BMC Ophthalmology
Background to analyze, at one year, the efficacy and safety of treat-and-extend (T&E) intravitreal (IV) Brolucizumab in patients affected by macular neovascularization (MNV).
Francesco Faraldi, Carlo Alessandro Lavia, Marco Nassisi, Raphael Kilian, Clara Rizzo, Maria Cristina Savastano, Stanislao Rizzo, Fabrizio Giansanti, Daniela Bacherini   +8 more
doaj   +2 more sources

Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy [PDF]

Ophthalmology and Therapy, 2023
Introduction To evaluate the real-world efficacy of aflibercept using the treat-and-extend (TnE) regimen in treating neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV), and to analyze biomarkers using optical ...
Chu-Hsuan Huang, Tso-Ting Lai, Chang-Hao Yang, Yi-Ting Hsieh   +3 more
doaj   +2 more sources

Recurrence of neovascular age-related macular degeneration after discontinuation of modified treat and extend treatment [PDF]

Scientific Reports
We evaluated the incidence and risk factors for recurrence in patients with neovascular age-related macular degeneration (nAMD) who discontinued anti-vascular endothelial growth factor (VEGF) therapy under a modified treat-and-extend (TAE) protocol.
Junwoo Lee, Jaehwan Choi, Seung-Young Yu, Kiyoung Kim   +3 more
doaj   +2 more sources

Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen [PDF]

Scientific Reports, 2022
The appropriate timing of treatment cessation after treat and extend (TAE) regimen for age-related macular degeneration has not been established. This study aimed to investigate the incidence and risk factors of recurrence after cessation of the TAE ...
Yuki Hirata, Akio Oishi, Yuki Maekawa, Eiko Tsuiki, Akira Machida, Junko Kurihara, Takashi Kitaoka   +6 more
doaj   +2 more sources

Treat and Extend Regimen of Aflibercept in the Treatment of Type 1 Choroidal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy: Three-year Follow-Up [PDF]

Clinical Ophthalmology
Taras B Kustryn, Oleg S Zadorozhnyy, Illia O Nasinnyk, Alla O Nevska, Kseniia V Troianovska, Nataliya V Pasyechnikova, Andrii R Korol Laser Microsurgery Department, The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of ...
Kustryn TB, Zadorozhnyy OS, Nasinnyk IO, Nevska AO, Troianovska KV, Pasyechnikova NV, Korol AR   +6 more
doaj   +2 more sources